227 related articles for article (PubMed ID: 23199545)
1. A new class of drug for the management of type 2 diabetes: sodium glucose co-transporter inhibitors: 'glucuretics'.
Chan HW; Ashan B; Jayasekera P; Collier A; Ghosh S
Diabetes Metab Syndr; 2012; 6(4):224-8. PubMed ID: 23199545
[TBL] [Abstract][Full Text] [Related]
2. Pharmacodynamics, efficacy and safety of sodium-glucose co-transporter type 2 (SGLT2) inhibitors for the treatment of type 2 diabetes mellitus.
Scheen AJ
Drugs; 2015 Jan; 75(1):33-59. PubMed ID: 25488697
[TBL] [Abstract][Full Text] [Related]
3. Sodium-glucose co-transport inhibitors: progress and therapeutic potential in type 2 diabetes mellitus.
Neumiller JJ; White JR; Campbell RK
Drugs; 2010 Mar; 70(4):377-85. PubMed ID: 20205482
[TBL] [Abstract][Full Text] [Related]
4. The Role of Sodium-Glucose Co-Transporter 2 Inhibitors in the Treatment of Type 2 Diabetes.
Whalen K; Miller S; Onge ES
Clin Ther; 2015 Jun; 37(6):1150-66. PubMed ID: 25891804
[TBL] [Abstract][Full Text] [Related]
5. Sodium glucose co-transporter 2 inhibitors and their mechanism for improving glycemia in patients with type 2 diabetes.
Davidson JA; Kuritzky L
Postgrad Med; 2014 Oct; 126(6):33-48. PubMed ID: 25414933
[TBL] [Abstract][Full Text] [Related]
6. [Sodium-glucose cotransporter type 2 inhibitors (SGLT2): from familial renal glucosuria to the treatment of type 2 diabetes mellitus].
Pérez López G; González Albarrán O; Cano Megías M
Nefrologia; 2010; 30(6):618-25. PubMed ID: 21113210
[TBL] [Abstract][Full Text] [Related]
7. [New possibility in the oral glucose lowering treatment of type 2 diabetes mellitus: sodium-glucose co-transporter-2 inhibitors].
Simonyi G
Orv Hetil; 2012 May; 153(18):695-701. PubMed ID: 22547464
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of the sodium glucose co-transporter-2: its beneficial action and potential combination therapy for type 2 diabetes mellitus.
Chen LH; Leung PS
Diabetes Obes Metab; 2013 May; 15(5):392-402. PubMed ID: 23331516
[TBL] [Abstract][Full Text] [Related]
9. [Sodium-glucose co-transporter-2 inhibitors: from the bark of apple trees and familial renal glycosuria to the treatment of type 2 diabetes mellitus].
Mauricio D
Med Clin (Barc); 2013 Sep; 141 Suppl 2():31-5. PubMed ID: 24444522
[TBL] [Abstract][Full Text] [Related]
10. [Dapagliflozin, the first SGLT-2 inhibitor in the treatment of type 2 diabetes].
Albarrán OG; Ampudia-Blasco FJ
Med Clin (Barc); 2013 Sep; 141 Suppl 2():36-43. PubMed ID: 24444523
[TBL] [Abstract][Full Text] [Related]
11. The potential role of sodium glucose co-transporter 2 inhibitors in combination therapy for type 2 diabetes mellitus.
Lajara R
Expert Opin Pharmacother; 2014 Dec; 15(17):2565-85. PubMed ID: 25316597
[TBL] [Abstract][Full Text] [Related]
12. Canagliflozin, a new sodium-glucose cotransporter 2 inhibitor, in the treatment of diabetes.
Nisly SA; Kolanczyk DM; Walton AM
Am J Health Syst Pharm; 2013 Feb; 70(4):311-9. PubMed ID: 23370138
[TBL] [Abstract][Full Text] [Related]
13. Remogliflozin etabonate, a selective inhibitor of the sodium-dependent transporter 2 reduces serum glucose in type 2 diabetes mellitus patients.
Dobbins RL; O'Connor-Semmes R; Kapur A; Kapitza C; Golor G; Mikoshiba I; Tao W; Hussey EK
Diabetes Obes Metab; 2012 Jan; 14(1):15-22. PubMed ID: 21733056
[TBL] [Abstract][Full Text] [Related]
14. Safety, pharmacokinetic, and pharmacodynamic profiles of ipragliflozin (ASP1941), a novel and selective inhibitor of sodium-dependent glucose co-transporter 2, in patients with type 2 diabetes mellitus.
Schwartz SL; Akinlade B; Klasen S; Kowalski D; Zhang W; Wilpshaar W
Diabetes Technol Ther; 2011 Dec; 13(12):1219-27. PubMed ID: 21854192
[TBL] [Abstract][Full Text] [Related]
15. SGLT2 inhibition with dapagliflozin -- a novel approach for the management of type 2 diabetes.
Kilov G; Leow S; Thomas M
Aust Fam Physician; 2013 Oct; 42(10):706-10. PubMed ID: 24130972
[TBL] [Abstract][Full Text] [Related]
16. Sodium-glucose co-transporter 2 inhibitors for type 2 diabetes mellitus: An overview for the primary care physician.
Dandona P; Chaudhuri A
Int J Clin Pract; 2017 May; 71(5):. PubMed ID: 28440009
[TBL] [Abstract][Full Text] [Related]
17. Tofogliflozin, a novel sodium-glucose co-transporter 2 inhibitor, improves renal and pancreatic function in db/db mice.
Nagata T; Fukuzawa T; Takeda M; Fukazawa M; Mori T; Nihei T; Honda K; Suzuki Y; Kawabe Y
Br J Pharmacol; 2013 Oct; 170(3):519-31. PubMed ID: 23751087
[TBL] [Abstract][Full Text] [Related]
18. Remogliflozin etabonate: a novel SGLT2 inhibitor for treatment of diabetes mellitus.
Mikhail N
Expert Opin Investig Drugs; 2015; 24(10):1381-7. PubMed ID: 26288025
[TBL] [Abstract][Full Text] [Related]
19. Sodium glucose co-transporter 2 inhibitors: blocking renal tubular reabsorption of glucose to improve glycaemic control in patients with diabetes.
Jabbour SA; Goldstein BJ
Int J Clin Pract; 2008 Aug; 62(8):1279-84. PubMed ID: 18705823
[TBL] [Abstract][Full Text] [Related]
20. Sodium glucose co-transporter 2 (SGLT2) inhibition with canagliflozin in type 2 diabetes mellitus.
Said S; Hernandez GT
Cardiovasc Hematol Agents Med Chem; 2013 Sep; 11(3):203-6. PubMed ID: 24025022
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]